OPKO Health submits de novo request to FDA for the 4Kscore® test
OPKO Health announced it has submitted a de novo request to the FDA seeking regulatory clearance for the 4Kscore® test. The 4Kscore® test is a blood test used by health care professionals to assess a patient’s risk of having aggressive prostate cancer after an abnormal PSA test result. June 20, 2019